Evidence map›Paper›PMID 40021963›Full record

ArticleBMC public health2025

Implementing SARS-CoV-2 routine surveillance in antenatal care in Zambia, 2021-2022: best practices and lessons learned.

Tannia Tembo, Elizabeth Heilmann, Bupe Mulenga Kabamba, Sombo Fwoloshi, Kalubi Kalenga, Felix Chilambe, Mpanji Siwinga, Marie-Reine Rutagwera, Maximillian Musunse, Chabu Kangale and 8 more

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tannia TemboCentre for Infectious Disease Research in Zambia (CIDRZ), P.O Box 34681, Lusaka, Zambia. Taniya.Tembo@cidrz.org.
Elizabeth HeilmannPublic Health Institute, Oakland, CA, USA.
Bupe Mulenga KabambaPATH, Lusaka, Zambia.
Sombo FwoloshiUniversity Teaching Hospital, Lusaka, Zambia.
Kalubi KalengaCentre for Infectious Disease Research in Zambia (CIDRZ), P.O Box 34681, Lusaka, Zambia.
Felix ChilambeUniversity Teaching Hospital, Lusaka, Zambia.
Mpanji SiwingaUniversity Teaching Hospital, Lusaka, Zambia.
Marie-Reine RutagweraPATH, Lusaka, Zambia.
Maximillian MusunsePATH, Lusaka, Zambia.
Chabu KangalePATH, Lusaka, Zambia.
Samuel YingstU.S. Centers for Disease Control and Prevention, Lusaka, Zambia.
Ruchi YadavU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Theodora SavoryCentre for Infectious Disease Research in Zambia (CIDRZ), P.O Box 34681, Lusaka, Zambia.
Julie R GutmanU.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Izukanji SikazweCentre for Infectious Disease Research in Zambia (CIDRZ), P.O Box 34681, Lusaka, Zambia.
Lloyd B MulengaUniversity Teaching Hospital, Lusaka, Zambia.
Carolyn Bolton Moore *Centre for Infectious Disease Research in Zambia (CIDRZ), P.O Box 34681, Lusaka, Zambia.
Jonas Z Hines *U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.

Funding

CDC HHS NU2GGH002251-01-00
6 · The paper itself

Abstract

backgroundIn Zambia, the true extent of SARS-CoV-2 infections is unknown because initial surveillance focused on patients with symptoms or severe disease. Antenatal sentinel surveillance had not been used to assess infection trends. The ANC COVID-19 surveillance study sought to determine SARS-CoV-2 seroprevalence and COVID-19 vaccine uptake among pregnant women. We provide insight into the study implementation, challenges encountered, best practices, and lessons learned.

methodsA repeated cross-sectional seroprevalence survey was implemented at 39 health facilities in four districts from September 2021 to September 2022. Pregnant women aged 15-49 years were enrolled at their first antenatal care visits. An electronic questionnaire gathered demographics and other COVID-19 related information from consenting participants. A dried blood sample was collected to detect IgG antibodies using a multiplex bead assay. Seropositive results were categorized as infection, infection and vaccination or infection based on anti-RBD and anti-nucleocapsid test results. Problems and their root causes were identified as they occurred. Practical problem-solving strategies were devised, implemented, and monitored to ensure that goals were accomplished.

resultsIn the primary analysis, 7% of the 9,221 samples collected from participants were not tested because they were missing. COVID-19 vaccine uptake of 9,111 pregnant women was assessed. Approximately 64% of participants were cumulatively seropositive for SARS-CoV-2 antibodies. Seroprevalence increased from 27.8% in September 2021 to 56.6% in July 2022. We observed an increase in vaccine coverage (0.5-27%) over time. Women aged 40-49 years old, without education and with prior COVID-19 infection were associated with higher vaccine uptake. The Delta variant of COVID-19 and the reallocation of health facilities between two partners delayed surveillance activities and increased the cost of implementation (e.g., the purchase of additional calibration and validation kits and DBS cards). Protocol deviations were attributed to the lack of experience in conducting research but, the district RAs repeatedly trained health facility staff to enhance their research knowledge.

conclusionsIncorporating SARS-CoV-2 surveillance into routine antenatal care is feasible and potentially sustainable when existing health system infrastructure, human resources, and surveillance systems are leveraged. Yet, careful planning is needed to anticipate implementation challenges and ensure high-quality data collection.

Indexed as

COVID-19Pregnancy Complications, InfectiousPrenatal CareAdolescentAdultCOVID-19 VaccinesCross-Sectional StudiesFemaleHumansMiddle AgedPregnancySARS-CoV-2Seroepidemiologic StudiesYoung AdultZambiaCOVID-19 VaccinesCOVID-19Prenatal careSARS-CoV-2Sentinel surveillanceSeroprevalence

Identifiers

PMID40021963
PMCPMC11869463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.